- Home
- GILT vs TYRA Comparison
GILT vs TYRA Comparison
Compare GILT & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILT
- TYRA
- Stock Information
- Founded
- GILT 1987
- TYRA 2018
- Country
- GILT Israel
- TYRA United States
- Employees
- GILT N/A
- TYRA N/A
- Industry
- GILT Radio And Television Broadcasting And Communications Equipment
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- GILT Technology
- TYRA Health Care
- Exchange
- GILT Nasdaq
- TYRA Nasdaq
- Market Cap
- GILT 400.3M
- TYRA 422.6M
- IPO Year
- GILT 1993
- TYRA 2021
- Fundamental
- Price
- GILT $6.13
- TYRA $8.92
- Analyst Decision
- GILT Strong Buy
- TYRA Strong Buy
- Analyst Count
- GILT 2
- TYRA 6
- Target Price
- GILT $8.50
- TYRA $30.50
- AVG Volume (30 Days)
- GILT 263.8K
- TYRA 353.6K
- Earning Date
- GILT 05-07-2025
- TYRA 05-08-2025
- Dividend Yield
- GILT N/A
- TYRA N/A
- EPS Growth
- GILT 6.30
- TYRA N/A
- EPS
- GILT 0.44
- TYRA N/A
- Revenue
- GILT $305,448,000.00
- TYRA N/A
- Revenue This Year
- GILT $45.29
- TYRA N/A
- Revenue Next Year
- GILT $11.74
- TYRA N/A
- P/E Ratio
- GILT $14.07
- TYRA N/A
- Revenue Growth
- GILT 14.79
- TYRA N/A
- 52 Week Low
- GILT $4.04
- TYRA $6.42
- 52 Week High
- GILT $8.05
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- GILT 45.95
- TYRA 45.95
- Support Level
- GILT $6.00
- TYRA $8.23
- Resistance Level
- GILT $6.39
- TYRA $8.80
- Average True Range (ATR)
- GILT 0.31
- TYRA 0.70
- MACD
- GILT 0.04
- TYRA 0.19
- Stochastic Oscillator
- GILT 74.77
- TYRA 75.30
About GILT Gilat Satellite Networks Ltd.
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs) and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.